Intranasal Bismuth Subgallate Paste for Epistaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nosebleeds (epistaxis) are inadequate, with limited immediate options available, and existing methods often rely on mechanical pressure or cauterization, which can be ineffective or lead to unpredictable bleeding.
Innovation Solution
A topical composition combining bismuth subgallate and a vasoconstriction agent, such as oxymetazoline, is applied intranasally to slow or stop nasal bleeding by reducing blood vessel diameter and promoting hemostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mechanical pressure devices (intranasal balloon, clamps, soft sponges) are used to control nosebleeds, then immediate treatment is available, but the treatment is often ineffective or leads to unpredictable bleeding
Solution Approach 1:
The invention changes the chemical parameters of the treatment by using bismuth subgallate (a hemostatic agent) combined with vasoconstriction agents (oxymetazoline, phenylephrine, or epinephrine) in specific concentrations (0.01-10%, 0.1-5%, or 0.001-0.5% respectively). This chemical approach replaces mechanical pressure devices with a pharmacological solution that reliably stops bleeding through vasoconstriction and hemostatic action, eliminating the unpredictability of mechanical methods while maintaining simplicity of application.
Solution Approach 2:
The invention substitutes mechanical pressure devices (balloons, clamps, sponges) with a chemical/pharmacological system. Instead of relying on mechanical compression to stop bleeding, the composition uses vasoconstriction agents to chemically narrow blood vessels and bismuth subgallate to promote clotting, providing reliable hemostasis without the need for complex mechanical apparatus.
2Reliability
If cauterization (electric or chemical agents) is used to treat nasal bleeding sites, then bleeding control is achieved, but unpredictable bleeding develops after the procedure
Solution Approach 1:
The invention changes the treatment parameters from aggressive cauterization (high heat or concentrated chemicals) to a more controlled pharmacological approach using vasoconstriction agents at controlled concentrations (0.001-10%) combined with bismuth subgallate. This gradual, chemical approach to hemostasis avoids the tissue damage and unpredictable rebound bleeding associated with cauterization, providing reliable bleeding control without harmful aftereffects.
Solution Approach 2:
The invention applies a protective approach by using a combination of bismuth subgallate and vasoconstriction agents that gently constrict blood vessels and promote clotting without causing tissue necrosis or damage. This 'cushioned' hemostatic action prevents the formation of unstable clots that could lead to unpredictable bleeding after treatment, unlike the aggressive tissue destruction caused by cauterization.
3Ease of operation
If conventional treatments (pinching, ice packs, downward head position) are used for nosebleeds, then immediate treatment is available, but these treatments are inadequate for controlling bleeding
Solution Approach 1:
The invention introduces a pharmaceutical intermediary (bismuth subgallate combined with vasoconstriction agents) that mediates between the simple application method and effective bleeding control. The composition can be easily applied topically like conventional treatments, but the active pharmaceutical ingredients provide reliable hemostasis through vasoconstriction and hemostatic action, bridging the gap between ease of use and treatment effectiveness.
Solution Approach 2:
The invention uses a composite pharmaceutical composition combining bismuth subgallate (hemostatic agent) with vasoconstriction agents (oxymetazoline, phenylephrine, or epinephrine). This composite material provides both the ease of topical application like conventional treatments and the reliable bleeding control that simple mechanical methods cannot achieve, combining multiple therapeutic mechanisms in one formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively slows or stops nasal bleeding, as demonstrated by examples where it was used to treat recurrent and profuse nosebleeds without recurrence after application, even in cases with incomplete control from conventional treatments.
Implementation Method 1
Bismuth subgallate is a well-known hemostatic agent that has been used for decades to control bleeding
Implementation Method 2
a vasoconstriction agent, such as oxymetazoline, is applied intranasally to slow or stop nasal bleeding by reducing blood vessel diameter
Data Source
AI summary
A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.